Inactive Instrument

Press Releases Teva Pharmaceutical Industries Limited Other OTC

Equities

TEVJF

IL0006290147

Press Releases

Unlock all the news: Be the first to know and act before the market!

Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	05/06	BU
Teva Pharmaceuticals - New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY Extended-Release Injectable Suspension from Invega Sustenna	03/06	AQ
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)	01/06	BU
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024	01/06	BU
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)	30/05	BU
Teva and Alvotech Announce SIMLANDI Injection Now Available in the U.S.	22/05	AQ
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.	21/05	BU
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.	21/05	AQ
New EVP, Teva Global Operations appointed	16/05	AQ
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations	15/05	BU
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	09/05	AQ
Teva Pharmaceutical Industries : Immediate Report	09/05	PU
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook	08/05	BU
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets	03/05	AQ
Teva to Present at the 2024 Bank of America Healthcare Conference	03/05	BU
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets	02/05	BU
Alvotech - U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-FreeInterchangeable Biosimilar to Humira	01/05	AQ
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)	30/04	BU
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO Tablets	17/04	AQ
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	17/04	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 03:11 pm IST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 03, 2023 at 12:49 am IST